Comparison of bipolar disorder type II and major depressive disorder.
Miola A, Tondo L, Pinna M, Contu M, Baldessarini RJ.
J Affect Disord. 2023 Feb 15;323:204-212. doi: 10.1016/j.jad.2022.11.039. Epub 2022 Nov 21.
Extracellular vesicle biomarkers for complement dysfunction in schizophrenia.
Xue T, Liu W, Wang L, Shi Y, Hu Y, Yang J, Li G, Huang H, Cui D.
Brain. 2024 Mar 1;147(3):1075-1086. doi: 10.1093/brain/awad341.
Childhood Trauma and Psychosis: An Updated Review.
Stanton KJ, Denietolis B, Goodwin BJ, Dvir Y.
Child Adolesc Psychiatr Clin N Am. 2020 Jan;29(1):115-129. doi: 10.1016/j.chc.2019.08.004. Epub 2019 Sep 23.
Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention.
Fusar-Poli P, Salazar de Pablo G, Correll CU, Meyer-Lindenberg A, Millan MJ, Borgwardt S, Galderisi S, Bechdolf A, Pfennig A, Kessing LV, van Amelsvoort T, Nieman DH, Domschke K, Krebs MO, Koutsouleris N, McGuire P, Do KQ, Arango C.
JAMA Psychiatry. 2020 Jul 1;77(7):755-765. doi: 10.1001/jamapsychiatry.2019.4779.
Risk Factors, Clinical Features, and Polygenic Risk Scores in Schizophrenia and Schizoaffective Disorder Depressive-Type.
Dennison CA, Legge SE, Hubbard L, Lynham AJ, Zammit S, Holmans P, Cardno AG, Owen MJ, O'Donovan MC, Walters JTR.
Schizophr Bull. 2021 Aug 21;47(5):1375-1384. doi: 10.1093/schbul/sbab036.
Antidepressant-associated diagnostic change from major depressive to bipolar disorder.
Tondo L, Miola A, Pinna M, Contu M, Baldessarini RJ.
Acta Psychiatr Scand. 2024 Sep;150(3):126-137. doi: 10.1111/acps.13721. Epub 2024 Jun 24.
Genetic insights into psychotic major depressive disorder: bridging the mood-psychotic disorder spectrum.
Nguyen TD, Meijsen JJ, Sigström R, Kuja-Halkola R, Xiong Y, Harder A, Kowalec K, Pasman JA, Scarpa C, Hörbeck E, Jonsson L, Hägg S, Mullins N, O'Connell KS, Dalman C, Helenius D, Zetterberg R, Larsson H, Lichtenstein P, Andreassen OA, Werge T, Buil A, Landén M, Sullivan PF, Lu Y.
EBioMedicine. 2025 Feb;112:105576. doi: 10.1016/j.ebiom.2025.105576. Epub 2025 Jan 30.
[Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
Auxéméry Y.
Encephale. 2012 Oct;38(5):373-80. doi: 10.1016/j.encep.2011.12.003. Epub 2012 Jan 24.
What we know and what we don't know about the treatment of schizoaffective disorder.
Murru A, Pacchiarotti I, Nivoli AM, Grande I, Colom F, Vieta E.
Eur Neuropsychopharmacol. 2011 Sep;21(9):680-90. doi: 10.1016/j.euroneuro.2011.03.001. Epub 2011 May 12.
Pharmacologic treatment of schizoaffective disorder.
Keck PE Jr, McElroy SL, Strakowski SM, West SA.
Psychopharmacology (Berl). 1994 May;114(4):529-38. doi: 10.1007/BF02244982.
